Anti-MUC1 CAR-pNK cells- PersonGen Biomedicine

Drug Profile

Anti-MUC1 CAR-pNK cells- PersonGen Biomedicine

Alternative Names: Anti-MUC1 chimeric antigen receptor natural killer cells - PersonGen Biomedicine; Anti-mucin1 chimeric antigen receptor natural killer cell therapy - PersonGen Biomedicine

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PersonGen Biomedicine
  • Class Antineoplastics; Cell therapies; Gene therapies
  • Mechanism of Action Gene transference; Mucin 1 inhibitors; Natural killer cell receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Jul 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (Parenteral) (NCT02839954)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top